SCHEMBL30329683

SCHEMBL30329683

CNc1cc(C)nc(Nc2cc3c(c(Br)c2C)OCO3)n1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ KCNH2 Q12809 1/20 0.37
▸ HAVCR2 Q8TDQ0 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ EHMT2 Q96KQ7 11/20 0.33
▸ EHMT1 Q9H9B1 10/20 0.33
▸ EPHB4 P54760 1/20 0.33
▸ NOS3 P29474 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ ALOX15 P16050 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25166003 1.00 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL25166700 0.90 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL30329725 0.90 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL30329661 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL25166015 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL30329841 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL25166482 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL25166431 0.81 HAVCR2 (0.41) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL30330177 0.81 HAVCR2 (0.41) ALDH1A1KDM4EHPGDHSD17B10KCNH2
SCHEMBL25166176 0.80 ALDH1A1 (0.35) ALDH1A1MAPTEHMT2EHMT1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 — — US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 — — CN disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 ALDH1A1 163/4885KDM4E 420/4885HPGD 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback